Ascentage Pharma’s APG-2449 Advances to Phase III

Ascentage Pharma Group International (HK:6855) has released an update.

Ascentage Pharma Group International has announced that its drug APG-2449, a treatment for non-small cell lung cancer (NSCLC), has received approval from China’s drug evaluation agency to proceed to Phase III trials. These trials will test the drug’s efficacy and safety in both treatment-resistant and treatment-naïve patients, addressing an urgent need for new therapies in light of resistance to current treatments. APG-2449 has shown promise in early trials, including the ability to cross the blood-brain barrier and potential benefits for patients with a specific type of lung cancer.

For further insights into HK:6855 stock, check out TipRanks’ Stock Analysis page.